RESEARKA

HOME PAPERS ALPHA DECISIONS RUBRIC SUBMIT ABOUT

CLAIM CARDS

Claim Cards

Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.

This synthesis tests the thesis that evidence for Aerobic exercise is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Contradiction: none

Sources: 5

Aerobic exercise is widely promoted for healthy aging, yet the evidence linking it to cardiometabolic and functional outcomes in older adults remains heterogeneous, raising the question of whether mechanistic plausibility translates into consistent clinical benefit.

Contradiction: none

Sources: 5

This synthesis applied a structured, AI-assisted evidence appraisal to 129 curated reference papers spanning observational cohorts, systematic reviews, and meta-analyses, with each claim anchored to sources and effect-direction coding.

Contradiction: none

Sources: 5

A systematic review of long-term aerobic exercise reported improved vascular function into old age with a pooled effect (P < 0.001), yet individual studies frequently returned null cardiometabolic results, creating cross-study disagreements across outcome classes in the evidence matrix (Campbell 2019).

Contradiction: none

Sources: 5

We conclude that aerobic exercise possesses genuine mechanistic support—particularly for inflammation and vascular function—but the anti-aging clinical case as currently constituted is incomplete: functional outcomes are inconsistent, drug–exercise interactions selectively suppress expected adaptations, and boundary conditions for dose, modality, and comorbidity status remain to be established by adequately powered trials.

Contradiction: none

Sources: 5

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-aerobic_exercise-v06-FINALREVIEWER-2026-05-17T11-26-01Z`.

Contradiction: none

Sources: 5

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.

Contradiction: none

Sources: 5

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.

Contradiction: none

Sources: 5

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual other, deficiency and prevalence, dosing and pharmacokinetics, frailty, immune, longevity, mortality and survival, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

Contradiction: none

Sources: 5

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

Contradiction: none

Sources: 5

| Contextual Other | n=70; claims=1888 | null signal in 62/70 sources | 60 indirect; 10 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Muscle Function | n=26; claims=941 | null signal in 16/26 sources | 22 indirect; 4 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Cardiometabolic | n=19; claims=693 | null signal in 16/19 sources | 17 indirect; 2 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Frailty | n=4; claims=62 | null signal in 2/4 sources | 4 indirect | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Dosing Pharmacokinetics | n=2; claims=40 | null signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Deficiency Prevalence | n=1; claims=9 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

Contradiction: none

Sources: 5

| Mortality Survival | n=1; claims=3 | null signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

Contradiction: none

Sources: 5

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contradiction: none

Sources: 5

70 included sources were assigned to this outcome class. Directional coding: negative=1, null=62, positive=4, unclear=3. Directness coding: indirect=60, review=10.

Contradiction: none

Sources: 5

26 included sources were assigned to this outcome class. Directional coding: mixed=2, negative=2, null=16, positive=3, unclear=3. Directness coding: indirect=22, review=4.

Contradiction: none

Sources: 5

19 included sources were assigned to this outcome class. Directional coding: negative=1, null=16, unclear=2. Directness coding: indirect=17, review=2.

Contradiction: none

Sources: 5

5 included sources were assigned to this outcome class. Directional coding: null=2, unclear=3. Directness coding: indirect=4, review=1.

Contradiction: none

Sources: 5

4 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=1, null=2. Directness coding: indirect=4.

Contradiction: none

Sources: 5

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=2.

Contradiction: none

Sources: 5

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Contradiction: none

Sources: 5

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Contradiction: none

Sources: 5

The curated corpus is dominated by observational cohort designs, with no long-term mortality-focused randomized controlled trial of aerobic exercise in non-diabetic older adults included. Outcomes related to all-cause mortality and hard cardiovascular events were addressed only indirectly — for example, Moore 2012 and Mok 2019 reported pooled cohort associations between leisure-time physical activity and mortality, but neither constituted a controlled intervention trial. Consequently, causal claims linking aerobic exercise to survival benefit in this synthesis remain inferred rather than demonstrated. This gap is clinically significant because mortality reduction is often the ultimate justification for exercise prescription in aging guidelines, yet the corpus lacks the trial-level evidence needed to confirm or quantify that benefit.

Contradiction: none

Sources: 5

Several outcome domains are represented by a single study within the corpus, precluding internal replication or meta-analytic pooling. For instance, Konopka 2019 alone examined the interaction between metformin and aerobic exercise on mitochondrial adaptations, while Gillen 2016 alone compared sprint interval training to moderate-intensity continuous training for cardiometabolic outcomes. Single-trial findings cannot be cross-validated within the synthesis, leaving their effect-size estimates vulnerable to idiosyncratic sample characteristics. Similarly, dose-response evidence for aerobic exercise on cognition rests on a single pilot RCT (Vidoni 2015), and no other included study directly tests dose as a moderating variable for cognitive endpoints.

Contradiction: none

Sources: 5

Where the corpus has mechanistic or biological-plausibility evidence, clinical claims remain inadequately supported. Yet no included study links these mechanistic changes to downstream clinical endpoints such as hospitalization, disability-free survival, or quality-adjusted life years. This mechanism-to-clinic gap means that the synthesis cannot bridge from biological signal to treatment recommendation without additional trial evidence that connects the intermediate biomarker changes to patient-relevant outcomes.

Contradiction: none

Sources: 5

The final interpretation is deliberately tiered. Aerobic Exercise has a biologically plausible geroscience rationale and selected clinical signals, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence.

Contradiction: none

Sources: 5

In advanced atherosclerotic Apoe-/- mouse models, does ABT-263 senolytic treatment support a narrow warning that senescent-cell clearance can reduce smooth-muscle-associated plaque features while simultaneously increasing endothelial-to-mesenchymal transition and mortality risk, and should this signal be framed as a therapeutic-window concern rather than as evidence that senolytics are broadly harmful or broadly beneficial?

Contradiction: none

Sources: 4

This submission uses the retained Researka v4 senolytic evidence run from 2026-05-17. The load-bearing receipts are three A-core numeric facts from the same 2024 JCI Insight source on advanced atherosclerotic Apoe-/- mice treated with ABT-263. Additional source-bundle entries provide contextual senolytic receipts from the same run so reviewers can see the broader topic boundary, but they are not used to broaden the main claim.

Contradiction: none

Sources: 4

The central evidence is source-concentrated and preclinical. That is acceptable only for a frontier warning memo because the signal is counter-consensus and internally coherent: the same model/source reports plaque-cell reduction, EndoMT increase, and mortality risk. Contextual bundle papers cover adjacent senolytic biology, but the thesis should remain limited to advanced plaque biology and ABT-263 rather than general anti-aging use.

Contradiction: none

Sources: 4

fact_id=12624: increased EC contributions to lesions via EC-to-mesenchymal transition (EndoMT) by 60% in advanced atherosclerotic Apoe-/- mice fed western diet; intervention: ABT-263 at 100 mg/kg or 50 mg/kg; source DOI: 10.1172/jci.insight.173863

Contradiction: none

Sources: 4

Taken together, these receipts support a narrow interpretation: ABT-263 may clear or reduce plaque-associated smooth muscle cells while worsening features linked to plaque instability and survival. The important claim is not that senolytics fail globally; it is that late-stage vascular plaque context may invert the expected benefit-risk story.

Contradiction: none

Sources: 4

Useful falsification work includes independent replication in advanced plaque models, dose-response separation of smooth-muscle-cell loss from EndoMT induction, comparison with non-ABT-263 senolytics, and human vascular safety evidence. A broader review should also test whether earlier-stage plaque, lower-dose exposure, or intermittent treatment changes the direction of the risk signal.

Contradiction: none

Sources: 4

The current evidence supports submitting a cautious Researka alpha memo: senolytic ABT-263 may backfire in advanced plaques by coupling plaque-cell reduction with EndoMT and mortality risk. The conclusion should be published only as a bounded frontier signal with explicit single-source and preclinical caveats, not as settled evidence against senolytic therapy.

Contradiction: none

Sources: 4

Source scope:** 16 A/B-bound receipts across 10 evidence sources; 12 total references in the source bundle. Two source-bundle entries are corpus-context references for breadth, not thesis proof; schema labels still use primary/review only.

Contradiction: none

Sources: 5

The exercise corpus in this run supports a broader alpha signal: exercise effects are endpoint- and context-specific rather than uniformly generalizable. The strongest bound receipts span inflammatory markers, exercise capacity and mortality, tumor-model response, angiogenesis biomarkers, muscle-protein synthesis, peripheral oxygen extraction, dietary inflammatory index, and NO/exercise muscle effects.

Contradiction: none

Sources: 5

The common story treats exercise as a single beneficial geroscience intervention. This evidence map says the more useful signal is specificity: different populations, endpoints, and mechanisms move differently, so the publishable claim is not “exercise works,” but “exercise signals need endpoint- and context-specific interpretation.”

Contradiction: none

Sources: 5

`fact_id=12572` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`

Contradiction: none

Sources: 5

`fact_id=12573` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`

Contradiction: none

Sources: 5

`fact_id=12544` (`A_core`) — Mortality risk was 11% lower (hazard ratio, 0.89; 95% confidence interval, 0.86-0.93; P<0.001) for every 1-MET increase in exercise capacity. DOI `10.1161/hypertensionaha.114.03510`

Contradiction: none

Sources: 5

`fact_id=30392` (`A_core`) — IGF-I/IGFBP-3 ratio increased significantly in the diet + exercise group (+5.4%, P < 0.01) compared with control. DOI `10.1158/1055-9965.epi-13-0337`

Contradiction: none

Sources: 5

`fact_id=34200` (`A_core`) — NO-donor treatment with isosorbide dinitrate for 6 wk, in combination with voluntary exercise for 3 wk, increased muscle mass by 25% DOI `10.1152/ajpcell.00305.2011`

Contradiction: none

Sources: 5

2. Exercise-Induced Catecholamines Activate the Hippo Tumor Suppressor Pathway to Reduce Risks of Breast Cancer Development (2017). DOI `10.1158/0008-5472.can-16-3125` — `primary`

Contradiction: none

Sources: 5

10. Nitric oxide and voluntary exercise together promote quadriceps hypertrophy and increase vascular density in female 18-mo-old mice (2012). DOI `10.1152/ajpcell.00305.2011` — `primary`

Contradiction: none

Sources: 5

Do not treat exercise as one generic anti-aging lever in review or trial design. Split claims by endpoint family before making a broad conclusion: inflammation, tumor biology, vascular oxygenation, muscle synthesis, mortality/exercise capacity, and diet-linked biomarker changes are different evidence lanes.

Contradiction: none

Sources: 5

The topic is heterogeneous, so the memo should guide subtopic extraction rather than support one pooled treatment-effect claim.

Contradiction: none

Sources: 5

No A_core/B_context counter-evidence was classified in this run, but the heterogeneity of endpoints is itself a constraint on broad claims.

Contradiction: none

Sources: 5

Re-run counter-evidence search against each child topic so “no counter-evidence found” is not confused with proof of absence.

Contradiction: none

Sources: 5

Suggested citation:** Dom Lynch. (2026). Exercise signals are endpoint-specific, not uniformly generalizable. ReseaRka Evidence Index. Version 1.0.

Contradiction: none

Sources: 5

Telomere length emerges as a dualistic biomarker where elongation simultaneously lowers cardiovascular risk but elevates cancer susceptibility, with the magnitude of these effects critically modulated by genetic variants, measurement precision, and disease-specific contexts like pulmonary fibrosis.

Contradiction: none

Sources: 5

Known / obvious (do not republish): Telomere length shortens with age; Shorter telomeres are generally associated with higher mortality risk; Telomere length is influenced by genetic factors

Contradiction: none

Sources: 5

Real tension: Fact 1 shows genetically determined longer telomere length lowers coronary heart disease risk, while facts 4 and 7 indicate it raises cancer risk, creating a therapeutic dilemma.

Contradiction: none

Sources: 5

`fact_id=109012` (`A_core`) — Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) DOI `10.1111/acel.13017`

Contradiction: none

Sources: 5

`fact_id=109013` (`A_core`) — but raised risk of cancer (OR = 1.11, 95% CI: 1.06-1.16) DOI `10.1111/acel.13017`

Contradiction: none

Sources: 5

_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

Contradiction: none

Sources: 5

Genetically determined longer telomere length was associated with lowered risk of coronary heart disease (CHD; OR = 0.95, 95% CI: 0.92-0.98) _(alpha cues: translation_context)_

Contradiction: none

Sources: 5

Suggested citation:** Dom Lynch. (2026). The Telomere Length Paradox: Quantifying Trade-offs Between Cardioprotection and Carcinogenesis Across Subgroups. ReseaRka Evidence Index. Version 1.0.

Contradiction: none

Sources: 5

Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.

Contradiction: none

Sources: 5

What does the current evidence establish about Caloric Restriction and human geroscience? This synthesis tests the thesis that evidence for Caloric restriction is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Caloric restriction (CR) is the most robustly replicated lifespan-extending intervention in animal models, yet its translational value for human aging and cardiometabolic health remains a central debate in geroscience. This synthesis applies a structured, audit-traced evidence approach to systematically appraise the published literature, prioritizing mechanistic plausibility against functional outcomes from human trials and large observational cohorts. Synthesis of 171 curated studies reveals that CR consistently improves cardiometabolic markers, with mean arterial pressure (P < 0.05) and lipid-related risk factors (P < 0.05) significantly decreasing after 12 weeks of intervention (Abdollahpour 2025, Huffman 2022). Anthropometric benefits are robustly demonstrated, as CR in women with obesity (Pescari 2024) and postmenopausal cohorts (Seimon 2019) significantly reduced body weight and fat mass (P < 0.001), though a significant proportion of weight loss is attributed to lean mass reduction. The tension between mechanistic longevity benefits and clinical functional trade-offs is stark: CR induced positive cardiometabolic shifts (Yi 2025) yet failed to maintain bone mi

Contradiction: none

Sources: 5

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.

Contradiction: none

Sources: 5

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.

Contradiction: none

Sources: 5

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual other, deficiency and prevalence, dosing and pharmacokinetics, frailty, immune, immune and inflammation, longevity, mortality and survival, muscle function, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

Contradiction: none

Sources: 5

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

Contradiction: none

Sources: 5

| Contextual Other | n=83; claims=4657 | null signal in 56/83 sources | 4 direct; 66 indirect; 1 mechanistic; 12 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Cardiometabolic | n=53; claims=2850 | null signal in 31/53 sources | 2 direct; 43 indirect; 8 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Immune | n=8; claims=328 | null signal in 4/8 sources | 6 indirect; 2 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Muscle Function | n=6; claims=754 | null signal in 3/6 sources | 4 indirect; 2 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Immune Inflammation | n=5; claims=246 | null signal in 2/5 sources | 5 indirect | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Frailty | n=3; claims=113 | null signal in 2/3 sources | 3 indirect | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

| Skeletal Fracture Bone | n=2; claims=33 | null signal in 2/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |

Contradiction: none

Sources: 5

The cardiometabolic evidence base for caloric restriction encompasses a diverse range of study designs, including systematic reviews, clinical RCTs, and observational cohorts spanning diverse populations and durations. Tang 2021 conducted a pilot RCT in young adults, randomizing participants into caloric restriction (n = 14), rope-skipping exercise (n = 14), or combined groups, reporting improvements in cardiometabolic markers with mixed significance levels.

Contradiction: none

Sources: 5

Notably, several studies report null or mixed findings for cardiometabolic outcomes, creating tensions within the evidence base. Reljic 2021 found that whole-body electromyostimulation did not improve cardiometabolic health in obese metabolic syndrome patients during caloric restriction (negative effect direction). These discrepancies highlight the context-dependency of caloric restriction's cardiometabolic effects, which appear to vary by population, intervention duration, and specific metabolic endpoints examined.

Contradiction: none

Sources: 5

The corpus includes several trials that assessed weight loss trajectories during caloric restriction across diverse populations and study designs. In a trial of obese women, intermittent fasting combined with calorie restriction yielded a body weight decrease of 3.9 ± 1.4 kg in the lower-calorie group versus 2.5 ± 0.6 kg in the higher-fat group (P = 0.04), with fat mass decreasing similarly across groups (P < 0.0001) (Klempel 2012). These findings illustrate that caloric restriction magnitude and pattern modulate weight outcomes, though adherence and compensatory mechanisms may attenuate effects.

Contradiction: none

Sources: 5

A systematic review by Xu et al. comparing intermittent energy restriction with continuous energy restriction in patients with metabolic syndrome found equivalent improvements in waist circumference (mean difference = -0.47, 95% CI [-1.19, 0.25]) and triglycerides (mean difference favoring intermittent restriction but not reaching significance), suggesting that both regimens produce comparable cardiometabolic benefit (Xu 2023).

Contradiction: none

Sources: 5

Mechanistically, caloric restriction appears to modulate organ size and metabolic adaptation pathways. Falkenhain et al. reported from CALERIE 2 ancillary data that 25% caloric restriction over 24 months was associated with significant reductions in organ mass, contributing to observed metabolic slowing (P < 0.001 for weight and organ changes) (Falkenhain 2025). In a randomized trial, Kroeger et al. found that intermittent fasting combined with caloric restriction produced greater decreases in body weight (4 ± 1 kg) and waist circumference (6 ± 1 cm) compared with intermittent fasting alone (2 ± 1 kg; 3 ± 1 cm; P = 0.04 for weight difference), with improvements in adipokine profiles (P < 0.01 for leptin reduction) (Kroeger 2012).

Contradiction: none

Sources: 5

A within-corpus tension is evident between studies showing null effects of caloric restriction on certain cardiometabolic markers and those reporting benefit. Conversely, Kautzky et al. found that short-term caloric restriction enhanced psychological wellbeing and reduced overweight markers including BMI, body fat, and fatty liver index in healthy women (p ≤ 0.0001 for multiple measures), suggesting population-specific cardiometabolic responses (Kautzky 2021).

Contradiction: none

Sources: 5

Preclinical and mechanistic human studies provide further biological context. Velingkaar and colleagues showed that two-meal caloric restriction induced 12-hour rhythms and improved glucose homeostasis in a rodent model (P < 0.05 for glucose measures), suggesting that meal timing itself contributes to restriction-related benefits (Velingkaar 2021). These preclinical data collectively suggest that caloric restriction engages conserved molecular pathways across species, though translation to human aging outcomes remains incompletely demonstrated.

Contradiction: none

Sources: 5

Adherence to caloric restriction regimens is a critical determinant of outcomes, and several studies documented this challenge. These adherence findings suggest that real-world caloric restriction may be substantially more challenging than prescribed in controlled trials.

Contradiction: none

Sources: 5

Within the behavioral outcomes domain, the tension between short-term psychological benefit and long-term adherence is central. By contrast, Kautzky et al. found that short-term caloric restriction with biofeedback reduced psychological distress indices (p ≤ 0.0001) and improved wellbeing in healthy women without disordered eating history (Kautzky 2021). Pescari et al. conducted quantitative analysis of caloric restriction versus isocaloric diets in women with obesity and found significant changes in anthropometric and bioimpedance parameters across the intervention period (P < 0.001 for multiple measures), though the study did not report long-term psychological follow-up (Pescari 2024). These findings collectively suggest that the psychological impact of caloric restriction is population-dependent, with clinical populations potentially vulnerable to iatrogenic effects that healthy populations may not experience.

Contradiction: none

Sources: 5

The evidence base for deficiency prevalence under caloric restriction derives from two observational cohorts with distinct design features. He et al. 2017 and Ilyasova et al. 2018 analyzed data from the CALERIE 2 randomized clinical trial, enrolling 218 healthy volunteers randomized to a prescribed 25% caloric restriction arm (n = 143) or ad libitum control (n = 75) for 2 years, with urinary F2-isoprostanes as the primary oxidative status endpoint. Both studies thus addressed the intersection of caloric restriction with markers of oxidative burden, though in distinct populations and over different durations.

Contradiction: none

Sources: 5

Quantitative findings from both cohorts demonstrated significant shifts in oxidative and contaminant-related biomarkers. In the He et al. 2017 observational cohort, serum PCB levels increased while oxidative stress markers decreased following P-CR, with multiple endpoints reaching statistical significance (P < 0.02, P = 0.02, P = 0.04, P < 0.05, P = 0.01). Ilyasova et al. 2018 reported that urinary F2-isoprostane levels changed significantly in the caloric restriction group relative to controls across the 2-year CALERIE 2 trial, with key comparisons yielding P < 0.01, P < 0.05, P = 0.0001, P = 0.006, and P = 0.004. These convergent p-value profiles indicate that caloric restriction meaningfully alters the oxidative milieu, though the direction of contaminant mobilization introduces a countervailing signal. Per-study endpoint details and exact test statistics are provided in the evidence synthesis.

Contradiction: none

Sources: 5

Mechanistically, the discordance between reduced oxidative stress and increased serum PCBs under caloric restriction can be understood through lipolysis-mediated mobilization. The He et al. 2017 cohort, which specifically measured PCBs in obese adults undergoing P-CR, provides direct human evidence for this mobilization pathway. Preclinical data on caloric restriction have long established the antioxidant benefits, but the concurrent contaminant release represents a mechanistic risk that is unique to obese populations with substantial xenobiotic body burdens. The CALERIE 2 data from Ilyasova et al. 2018, focused on healthy non-obese volunteers, showed oxidative improvements without the same PCB mobilization concern, consistent with lower baseline contaminant stores.

Contradiction: none

Sources: 5

By contrast, the two cohorts present a tension that reflects population-level differences in caloric restriction outcomes. He et al. 2017 observed that oxidative stress markers decreased (P < 0.02, P = 0.01) while serum PCBs simultaneously increased (P = 0.02, P = 0.04, P < 0.05) in obese adults, suggesting that the net health impact of caloric restriction in this subgroup is not unambiguously favorable. Ilyasova et al. 2018, drawing on the CALERIE 2 randomized clinical trial with 218 participants, reported more uniformly beneficial oxidative outcomes (P < 0.01, P = 0.0001, P = 0.004) in a lean-to-overweight healthy cohort without the confound of contaminant mobilization. This divergence underscores that the metabolic context of the individual — particularly obesity status and baseline lipophilic contaminant burden — moderates the deficiency-prevalence profile of caloric restriction, and that aggregate statements about oxidative benefit may not generalize across populations.

Contradiction: none

Sources: 5

Quantitative findings from Margolis 2018 revealed several statistically significant associations across the measured metabolic parameters. The study reported p-values of P < 0.05 for five distinct comparisons, alongside one non-significant finding at P = 0.09. The pattern of results included both significant and non-significant outcomes across nitrogen balance and ammonia/urea turnover measures. These mixed findings, with five P < 0.05 values and one P = 0.09 result, suggest that the metabolic effects of potassium bicarbonate supplementation during energy restriction are context-dependent.

Contradiction: none

Sources: 5

Mechanistically, the rationale for examining potassium bicarbonate supplementation during caloric restriction relates to the acid-base perturbations that accompany energy restriction. When caloric intake is reduced, protein catabolism may increase, generating nitrogenous waste products and potentially altering whole-body ammonia and urea turnover. The study's focus on nitrogen balance reflects the broader concern that caloric restriction, while potentially beneficial for longevity markers, may compromise protein metabolism in older adults. This mechanistic pathway connects the dosing intervention to the observed metabolic outcomes.

Contradiction: none

Sources: 5

Within the caloric restriction evidence base, the dosing and pharmacokinetic outcome class remains sparsely populated, with Margolis 2018 providing the only curated reference addressing this specific domain. The pilot nature of the study, combined with the mixed pattern of statistical significance across measured endpoints, underscores the preliminary status of evidence regarding supplementation strategies during energy restriction. This heterogeneity within a single study highlights the need for larger, confirmatory trials to establish the boundary conditions for potassium bicarbonate dosing during caloric restriction in aging populations.

Contradiction: none

Sources: 5

The evidence base for caloric restriction (CR) and frailty outcomes draws on three distinct cohort designs examining older or sarcopenic populations.

Contradiction: none

Sources: 5

Quantitative findings across these cohorts show predominantly null or mixed effects on frailty-related endpoints. Justice 2021 found that geroscience biomarker changes reached p≤0.05 in the caloric restriction arm, but these biochemical shifts did not translate into clear frailty-relevant clinical improvement. Liu 2021b reported no quantitative effect sizes, instead framing CR as a potential strategy to delay frailty onset based on mechanistic reasoning.

Contradiction: none

Sources: 5

The direct receipts support a narrow working claim: Compared with control, exercise alone reduced hs-CRP [-30.2%; 95% CI, -50.3, -1.0]; exercise alone reduced hs-CRP and IL6 (-30.9%; 95% CI, -47.3, -9.5). The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.

Contradiction: none

Sources: 5

The useful signal is narrower than the topic label: the lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.

Contradiction: none

Sources: 5

`fact_id=12572` (`A_core`) — Mixed-muscle protein fractional synthetic rate increased by 42% at 3 h postexercise and 69% at 24 h postexercise in CON. DOI `10.1152/ajpendo.00600.2013`

Contradiction: none

Sources: 5

`fact_id=12544` (`A_core`) — Mortality risk was 11% lower (hazard ratio, 0.89; 95% confidence interval, 0.86-0.93; P<0.001) for every 1-MET increase in exercise capacity. DOI `10.1161/hypertensionaha.114.03510`

Contradiction: none

Sources: 5

`fact_id=30392` (`A_core`) — IGF-I/IGFBP-3 ratio increased significantly in the diet + exercise group (+5.4%, P < 0.01) compared with control. DOI `10.1158/1055-9965.epi-13-0337`

Contradiction: none

Sources: 5

_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._

Contradiction: none

Sources: 5

Suggested citation:** Dom Lynch. (2026). Exercise: single-source lead signal with broader context receipts. ReseaRka Evidence Index. Version 1.0.

Contradiction: none

Sources: 5

Priority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.

Contradiction: none

Sources: 5

What does the current evidence establish about Rapamycin and human geroscience? Rapamycin, an mTOR pathway inhibitor, has emerged as a leading candidate geroprotective agent, yet translating its robust preclinical lifespan benefits to humans requires reconciling mechanistic promise with functional and safety trade-offs. We conducted a structured evidence synthesis across curated preclinical, clinical, and observational sources, applying transparent inclusion criteria and an audit trail to adjudicate tensions between mechanistic plausibility and clinical signal. Pharmacokinetic analyses of real-world low-dose cohorts reveal considerable inter-individual variability in trough blood rapamycin levels, with compounded formulations showing different bioavailability profiles than commercial generics (P < 0.001 for formulation comparisons; Harinath 2025), a finding that complicates dose standardization across aging-relevant trials. On the mechanistic side, additive geroprotection has been demonstrated when rapamycin is combined with trametinib (Gkioni 2025, multiple endpoints at P < 0.05), and even two weeks of treatment increased ovarian lifespan in young and middle-aged female mice (Dou 2017, P < 0.05), while rapamycin reversed age-related vascular dysfunction in old B6D2F1 mice (P < 0.05 across endpoints; Lesniewski 2016). The weight of evidence supports rapamycin's mechanistic plausibility as a geroprotector—autophagy induction, senescence suppression, and imm

Contradiction: none

Sources: 5